Clearmind Medicine Inc. announced on July 7, 2026, the successful completion of a formulation feasibility study for its lead candidate, MEAI. The study supports the development of a potential new additional route of administration for the compound. Clearmind Medicine Inc. is a biopharmaceutical company focused on developing medicines for mental health.
